The pharmaceutical industry and natural products: historical status and new trends

Phytochemistry Reviews

Volumn 14, Issue 2, 2015, Pages 299-315

  David, Bruno ^a   Wolfender, Jean Luc ^b   Dias, Daniel A ^c  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Access and benefit sharing; Biodiversity; Drug discovery; High throughput screening (HTS); Pharmaceutical industry

Indexed keywords

EID: 84939879331     PISSN: 15687767     EISSN: 1572980X     Source Type: Journal    
DOI: 10.1007/s11101-014-9367-z     Document Type: Review

References (109)

1. Anonymous (1992) United Nations. Convention on biological diversity. http://www.cbd.int/doc/legal/cbd-en.pdf. Cited 20 May 2014
2. Anonymous (1973) Art 53 c of the The European Patent Convention, http://www.epo.org/law-practice/legal-texts/html/epc/2010/e/ar53.html Cited 20 May 2014
3. Anonymus (2011) The Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity. http://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf. Cited 20 May 2014
4. Attinger P (2008) La médecine mésopotamienne. Journal des Médecines Cunéiformes 11–12:1–96
5. Baker DD (2007) The value of natural products to future pharmaceutical discovery. Nat Prod Rep 27:1225–1244
6. Bauer RA, Wurst JM, Tan DS (2010) Expanding the range of ‘druggable’ targets with natural product-based libraries: an academic perspective. Curr Opin Chem Biol 14:308–314
7. Berenbaum MC (1989) What is Synergy? Pharmacol Rev 41:93–141
8. Beutler JA (2009) Natural products as a foundation for drug discovery. Curr Protoc Toxicol Supplement 46:9.11.1–9.11.21
9. Bhatnagar I, Se-Kwon K (2010) Marine antitumor drugs: status, shortfalls and strategies. Mar Drugs 8:2702–2720
10. Blunt JW, Copp BR, Munro MHG et al (2011) Marine natural products. Nat Prod Rep 28:196–268
11. Bruneton J (2009) Pharmacognosie, phytochimie, plantes médicinales. Paris, Tec & Doc – Lavoisier
12. Bunnage ME (2011) Getting pharmaceutical R&D back on target. Nat Chem Biol 7:335–339
13. Buriani A, Garcia-Bermejo ML, Bosisio E et al (2012) Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 140:535–544
14. Butler MS (2005) Natural products to drugs: natural products derived compounds in clinical trials. Nat Prod Rep 22:162–195
15. Challal S, Bohni N, Buenafe OE et al (2012) Zebrafish bioassay-guided microfractionation for the rapid in vivo identification of pharmacologically active natural products. Chimia 66:229–232
16. Chen S-L, Jiang J-G (2012) Application of gene differential expression technology in the mechanism studies of nature product-derived drugs. Expert Opin Biol Ther 12:823–839
17. Chen ST, Dou J, Temple R et al (2008) New therapies from old medicines. Nat Biotechnol 26:1077–1083
18. Chen CH, Dickman KG, Moriya M et al (2012) Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109:8241–8246
19. Colegate SM, Molyneux RJ (2008) Bioactive natural products: Detection, isolation and structure determination. CRC Press, Boca Raton
20. Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477
21. Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830:3670–3695
22. Cragg GM, Newman DJ, Snader KM (1997) Natural products in drug discovery and development. J Nat Prod 60:52–60
23. Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26:322–337
24. Dančík V, Seiler KP, Young DW et al (2010) Distinct biological network properties between the targets of natural products and disease genes. J Am Chem Soc 132:9259–9261
25. David B, Ausseil F (2014) David B, Ausseil F (2014) Chapter 44. In: Hostettmann J, Stuppner H, Marston A, Chen S (eds) Handbook of chemical and biological plant analytical methods, 1st edn. Wiley, New Jersey
26. Dewick PM (2009) Medicinal natural products: A biosynthentic approach, 3rd edn. Wiley, Great Britain
27. Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery. Metabolites 2:303–336
28. Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429
29. Eldridge GR, Vervoort HC, Lee CM et al (2002) High-Throughput Method for the Production and Analysis of Large Natural Product Libraries for Drug Discovery. Anal Chem 74:3963–3971
30. Erkens RHJ (2011) What every chemist should know about plant names. Nat Prod Rep 28:11–14
31. Farnsworth NR (1990) The role of ethnopharmacology in drug development. In: Chadwick DJ, Marsh J (eds) Bioactive compounds from plants. John Wiley and Sons, Chichester
32. Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43:218–227
33. Fitzgerald JB, Schoeberl B, Nielsen UB et al (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2:458–466
34. Frearson JA, Collie IT (2009) HTS and hit finding in academia–from chemical genomics to drug discovery. Drug Discov Today 14:1150–1158
35. Genilloud O (2012) Current challenges in the discovery of novel antibacterials from microbial natural products. Recent Patents on Anti-Infective Drug Dis 7:189–204
36. Gertsch J (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Plant Med 77:1086–1098
37. Gilbert N (2010) Biodiversity law could stymie research. Nature 463:598
38. Gilbert N (2012) Chinese herbal medicine breaks into EU market. Nature News Blog, http://blogs.nature.com/news/2012/04/chinese-herbal-medicine-breaks-into-eu-market.html Cited 20 May 2014
39. Hammerness P, Basch E, Ulbricht C et al (2003) St. John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44:271–282
40. Harvey AL (2008) Natural products in drug discovery. Drug Discovery Today 13:894–901
41. Helmstädter A, Staiger C (2013) Traditional use of medicinal agents: a valid source of evidence. Drug Discovery Today 19:4–7
42. Hoffman F, Kishter SR (2013) Botanical new drug applications - The Final Frontier. Herbalgram 99:66–69
43. Hong J (2011) Role of natural product diversity in chemical biology. Curr Opin Chem Biol 15:350–354
44. Jiang GC, Lin YC, Zhou SN et al (2000) Acta Sci. Nat. Univ. Sunyatseni 39:68
45. Jiang Y, David B, Tu PF et al (2010) Recent analytical approaches in quality control of traditional Chinese medicines- A review. Anal Chim Acta 657:9–18
46. Kingston DGI (2011) Modern natural products drug discovery and its relevance to biodiversity cConservation. J Nat Prod 74:496–511
47. Kleinrock M (2012) IMS institute for healthcare informatics—The global use of medicines: Outlook through 2016. www.theimsinstitute.org. Cited 20 May 2014
48. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220
49. Krohn K, Dai JQ, Floerke U et al (2005) Botryane metabolites from the fungus Geniculosporium sp. isolated from the marine red alga Polysiphonia. J Nat Prod 68:400–405
50. Kusari S, Hertweck C, Spiteller M (2012) Chemical ecology of endophytic fungi: origins of secondary metabolites. Chem Biol 19:792–798
51. Lamottke K, Ripoll C, Walczak R (2011) The roots of innovation. European Biopharmaceutical Review 15:52–56
52. Lauro G, Masullo M, Piacente S et al (2012) Inverse virtual screening allows the discovery of the biological activity of natural compounds. Bioorg & Med Chem 20:3596–3602
53. Lawson K (2013) Botanical and plant-derived drugs: Global markets. BCC Research, Wellesley
54. Li YG, Huang WJ, Huang SY et al (2012) Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem Biophys Res Comm 422:85–90
55. Macarrón R, Banks MN, Bojanic D et al (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188–195
56. Mackay M (1998) Prescribed drugs: a major cause of ill health. Aust Health Rev 21:260–266
57. Matias EFF, Alves EF, Santos BS et al (2013) Biological activities and chemical characterization of Cordia verbenacea DC. as tool to validate the ethnobiological usage. Evid Based Complement Alternat Med 2013:164215
58. Mayer AM, Glaser KB, Cuevas C et al (2010) The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 31:255–265
59. McChesney JD, Venkataraman SK, Henri JT (2007) Plant natural products: back to the future or into extinction? Phytochemistry 68:2015–2022
60. McWilliams A (2006) Plant-derived drugs: Products, technology, applications (BIO022D) BBC Research, http://www.bbcresearch.com Cited 20 May 2014
61. Michael S, Auld D, Klumpp C et al (2008) A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 6:637–657
62. Miller JS (2011) The discovery of medicines from plants: a current biological perspective. Econ Bot 65:396–407
63. Mishra BB, Tiwari VK (2011) Natural products: an evolving role in future drug discovery. Euro J Med Chem 46:4769–4807
64. Muller WE, Singer A, Wonnemann M (2001) Hyperforin - Antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34(suppl1):S98–S102
65. Naoghare PK, Song JM (2010) Chip-based high throughput screening of herbal medicines. Comb Chem High Throughout Screen 13:923–931
66. Newman DJ (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51:2589–2599
67. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477
68. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335
69. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022–1037
70. Ngo LT, Okogun JI, Folk WR (2013) 21st century natural product research and drug development and traditional medicines. Nat Prod Rep 30:584–592
71. Nicoletti M (2012) Nutraceuticals and botanicals: overview and perspectives. Int J Food Sci Nutr 63:2–6
72. Novodvorsky P, Da Costa MMJ, Chico TJA (2013) Zebrafish-based small molecule screens for novel cardiovascular drug. Drug Discov Today 10:e109–e114
73. Ortholand J-Y, Ganesan A (2004) Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 8:271–280
74. Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310:451–453
75. Posadzki P, Watson L, Ernst E (2013) Herbdrug interactions: an overview of systematic reviews. Br J Clin Pharmacol 75:603–618
76. Ribnicky DM, Poulev A, Schmidt B et al (2008) Evaluation of botanicals for improving human health. Am J Clin Nutr 87:472S–475S
77. Roessner U (2011) Metabolomics – The combination of analytical chemistry, biology and informatics. In: Moo-Young M (ed) Comprehensive Biotechnology, 2nd edn. Springer, Heidelberg, Germany
78. Rollinger JM (2011) Combination of ethnopharmacological knowhow with modern in silico tools. Planta Med 77:1230
79. Rollinger JM, Langer T, Stuppner H (2006) Strategies for efficient lead structure discovery from natural products. Curr Med Chem 13:1491–1507
80. Saklani A, Kutty SK (2008) Plant-derived compounds in clinical trials. DDT 13:161–171
81. Sativex (2013) http://www.sativex.co.uk/healthcare-professionals Cited 27 Oct 2013
82. Scheinfeld N (2008) Sinecatechins. Drugs Fut 33:27–30
83. Schmidt B, Ribnicky DM, Poulev A et al (2008) A natural history of botanical therapeutics. Metabolism 57:S3–S9
84. Schmitt EK, Moore CM, Krastel P et al (2011) Natural products as catalysts for innovation: a pharmaceutical industry perspective. Curr Opin Chem Biol 15:497–504
85. Sheridan C (2012) Recasting natural product research. Nat Biotechnol 30:385–387
86. Sertürner F (1817) Über das Morphium, eine neue salzfähige Grundlage und die Mekonsäure, als Hauptbestandtheile des Opiums. Ann Phys 55:56–89
87. Stickel F, Patsenker E, Schuppan D (2005) Herbal hepatotoxicity. J Hepatol 43:901–910
88. Swinney DC, Anthony J (2011) How where new medicine discovered? Nat Rev Drug Discov 10:507–519
89. Thomas GL, Johannes CW (2011) Natural product-like synthetic libraries. Curr Opin Chem Biol 15:516–522
90. U.S. Food and Drug Administration (2013) News and Events, FDA News Release (2012) FDA approves first anti-diarrheal drug for HIV/AIDS patients. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm. Cited 20 May 2014
91. van der Kooy F, Maltese F, Hae Choi Y et al (2009) Quality control of herbal material and phytopharmaceuticals with MS and NMR based metabolic fingerprinting. Planta Med 75:763–775
92. van Wietmarschen H, Yuan K, Lu C et al (2009) Systems Biology Guided by Chinese Medicine Reveals New Markers for Sub-Typing Rheumatoid Arthritis Patients. J Clin Rheumatol 15:330–337
93. Verpoorte R (2012) Good Practices: the basis for evidence-based medicines. J Ethnopharmacol 140:455–457
94. Verpoorte R, Choi YH, Kim HK (2005) Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol 100:53–56
95. Verpoorte R, Crommelin D, Danhof M et al (2009) Commentary: “A systems view on the future of medicine: inspiration from Chinese medicine?”. J Ethnopharmacol 121:479–481
96. Wagner H (2005) Natural products chemistry and phytomedicine in the 21st century: new developments and challenges. Pure Appl Chem 77:1–6
97. Wagner H (2011) Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 82:34–37
98. Wagner H, Ulrich-Merzenich G (2009) Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 16:97–110
99. Wang L, Chen C (2013) Emerging applications of metabolomics in studying chemopreventive phytochemicals. Aaps Journal 15:941–950
100. Wang M, Lamers R, Korthout H et al (2005a) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 19:173–182
101. Wang Y, Tang H, Nicholson JK et al (2005b) A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem 53:191–196
102. Woelk H (2000) Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 321:536–539
103. Wolfender J-L, Eugster PJ, Bohni N et al (2011) Advanced methods for natural product drug discovery in the field of nutraceuticals. Chimia 65:400–406
104. Xie G, Li X, Li H et al (2013) Toward personalized nutrition: comprehensive phytoprofiling and metabotyping. J Proteome Res 12:1547–1559
105. Yang M, Poon J, Wang S et al (2013) Application of Genetic Algorithm for Discovery of Core Effective Formulae in TCM Clinical Data. Comp. Math. Methods in Medicine 2013:1–16
106. Yuliana ND, Khatib A, Choi YH et al (2011) Metabolomics for bioactivity assessment of natural products. Phytother Res 25:157–169
107. Zhang HW, Song YC, Tan RX (2006) Biology and chemistry of endophytes. Nat Prod Rep 23:753–771
108. Zhang B, Peng Y, Zhang Z et al (2010) GAP production of TCM herbs in China. Planta Med 76:1948–1955
109. Zheng BC (1988) The earliest monograph on pharmaceuticals in China. J Tradit Chin Med 8:75–76